公开(公告)号：US09173844B2

公开(公告)日：2015-11-03

申请号：US13062389

申请日：2009-08-26

申请人： Kai Suzuki

发明人： Kai Suzuki

IPC分类号： A61K9/14 ,  A61K9/20

CPC分类号： A61K9/2018 ,  A61K9/2027

摘要： An object of the present invention is to provide a gradual disintegration-type, sustained-release pharmaceutical solid preparation whose pharmacologically active substance release behavior is controlled. The solid pharmaceutical preparation of the present invention is a matrix-type preparation containing: (a) a pharmacologically active substance; (b) calcium polycarbophil; and (c) a specific sugar and/or sugar alcohol.

摘要翻译： 本发明的目的是提供其药理学活性物质释放行为被控制的逐渐崩解型缓释药物固体制剂。 本发明的固体药物制剂是含有：（a）药理活性物质的基质型制剂; （b）聚卡波非钙; 和（c）特定的糖和/或糖醇。

公开(公告)号：US20110208913A1

公开(公告)日：2011-08-25

申请号：US13027338

申请日：2011-02-15

申请人： Kai Suzuki ,  Takahiro Fukushige ,  Tamaki Konno ,  Kouya Koba

发明人： Kai Suzuki ,  Takahiro Fukushige ,  Tamaki Konno ,  Kouya Koba

IPC分类号： G06F12/00

CPC分类号： G06F1/3203 ,  G06F1/266 ,  G06F1/3253 ,  Y02D10/151 ,  Y02D50/20

摘要： Disclosed herein is a storage device including: a communication execution unit configured to be capable of controlling an operation state between a communication-enabled state in which data communication is possible and a pause state in which data communication is impossible; a buffer configured to store data transmitted and received by the communication execution unit; a memory configured to be capable of storing data; a memory controller configured to carry out data input and output between the memory and the buffer; and a communication controller configured to make the communication execution unit operate if data communication is carried out, and make the communication execution unit take a pause if data communication is not carried out. The communication controller switches the operation state of the communication execution unit between the communication-enabled state and the pause state in data communication depending on a data processing state of the buffer.

摘要翻译： 这里公开了一种存储装置，包括：通信执行单元，被配置为能够控制可能进行数据通信的通信使能状态与数据通信不可能的暂停状态之间的操作状态; 缓冲器，其被配置为存储由所述通信执行单元发送和接收的数据; 被配置为能够存储数据的存储器; 存储器控制器，配置为在存储器和缓冲器之间执行数据输入和输出; 以及通信控制器，被配置为在进行数据通信时使通信执行单元工作，并且如果不执行数据通信，则使通信执行单元暂停。 通信控制器根据缓冲器的数据处理状态在数据通信中切换通信执行单元的通信使能状态和暂停状态之间的操作状态。

公开(公告)号：US20110165249A1

公开(公告)日：2011-07-07

申请号：US13062389

申请日：2009-08-26

申请人： Kai Suzuki

发明人： Kai Suzuki

IPC分类号： A61K9/14 ,  A61K31/55 ,  A61K31/522 ,  A61K31/47 ,  A61P7/00 ,  A61P9/00

CPC分类号： A61K9/2018 ,  A61K9/2027

摘要： An object of the present invention is to provide a gradual disintegration-type, sustained-release pharmaceutical solid preparation whose pharmacologically active substance release behavior is controlled. The solid pharmaceutical preparation of the present invention is a matrix-type preparation containing: (a) a pharmacologically active substance; (b) calcium polycarbophil; and (c) a specific sugar and/or sugar alcohol.

摘要翻译： 本发明的目的是提供其药理学活性物质释放行为被控制的逐渐崩解型缓释药物固体制剂。 本发明的固体药物制剂是含有：（a）药理活性物质的基质型制剂; （b）聚卡波非钙; 和（c）特定的糖和/或糖醇。

公开(公告)号：US20120166681A1

公开(公告)日：2012-06-28

申请号：US13327215

申请日：2011-12-15

申请人： Kai Suzuki

发明人： Kai Suzuki

IPC分类号： G06F3/00

CPC分类号： G06F13/4045 ,  G06F13/4295

摘要： An information processing device includes a serial transfer interface which performs serial transfer for data in a unit of packets between counterparty devices, a transfer control unit which performs control of data transfer of the serial transfer interface, and a transfer state monitoring unit which monitors a data transfer state including a data size being subjected to data transfer of the serial transfer interface, determines and can change the maximum data size of a transmission packet to be transmitted next according to the monitored state, and supplies the determined maximum data size to the transfer control unit, and the transfer control unit performs control of data transfer of the serial transfer interface according to the maximum data size of the transmission packet supplied from the transfer state monitoring unit.

摘要翻译： 一种信息处理装置，包括串行传送接口，其以对方单元之间的分组为单位进行数据的串行传送，执行串行传送接口的数据传送控制的传送控制单元和监视数据的传送状态监视单元 包括经过串行传送接口的数据传输的数据大小的传送状态根据监视状态确定并且可以改变下一个要发送的传输包的最大数据大小，并将确定的最大数据大小提供给传送控制 单元，并且传送控制单元根据从传送状态监视单元提供的传输分组的最大数据大小来执行串行传送接口的数据传送控制。

公开(公告)号：US08615626B2

公开(公告)日：2013-12-24

申请号：US13027338

申请日：2011-02-15

申请人： Kai Suzuki ,  Takahiro Fukushige ,  Tamaki Konno ,  Kouya Koba

发明人： Kai Suzuki ,  Takahiro Fukushige ,  Tamaki Konno ,  Kouya Koba

IPC分类号： G06F12/00

CPC分类号： G06F1/3203 ,  G06F1/266 ,  G06F1/3253 ,  Y02D10/151 ,  Y02D50/20

摘要： Disclosed herein is a storage device including: a communication execution unit configured to be capable of controlling an operation state between a communication-enabled state in which data communication is possible and a pause state in which data communication is impossible; a buffer configured to store data transmitted and received by the communication execution unit; a memory configured to be capable of storing data; a memory controller configured to carry out data input and output between the memory and the buffer; and a communication controller configured to make the communication execution unit operate if data communication is carried out, and make the communication execution unit take a pause if data communication is not carried out. The communication controller switches the operation state of the communication execution unit between the communication-enabled state and the pause state in data communication depending on a data processing state of the buffer.

摘要翻译： 这里公开了一种存储装置，包括：通信执行单元，被配置为能够控制可能进行数据通信的通信使能状态与数据通信不可能的暂停状态之间的操作状态; 缓冲器，其被配置为存储由所述通信执行单元发送和接收的数据; 被配置为能够存储数据的存储器; 存储器控制器，配置为在存储器和缓冲器之间执行数据输入和输出; 以及通信控制器，被配置为在进行数据通信时使通信执行单元工作，并且如果不执行数据通信，则使通信执行单元暂停。 通信控制器根据缓冲器的数据处理状态在数据通信中切换通信执行单元的通信使能状态和暂停状态之间的操作状态。

公开(公告)号：US20100323006A1

公开(公告)日：2010-12-23

申请号：US12665642

申请日：2008-06-20

申请人： Shinsuke Nakagawa ,  Kai Suzuki ,  Tadashi Mukai

发明人： Shinsuke Nakagawa ,  Kai Suzuki ,  Tadashi Mukai

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K31/55

CPC分类号： A61K31/55 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059

摘要： The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50 wt. % or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 μm, and a 90% cumulative particle diameter of 100 to 200 μm.

摘要翻译： 本发明提供了具有优异的崩解性和优异的溶解性的新型药物固体制剂，导致活性成分通过胃肠道的足够的吸收性。 本发明的药物固体制剂包含：（a）7-氯-5-羟基-1- [2-甲基-4-（2-甲基苯甲酰氨基）苯甲酰基] -2,3,4,5-四氢-1H- 苯并氮杂和/或其盐; （b）含羟基丙氧基的羟丙基纤维素的量为50重量％ ％以上; 和（c）选自羧甲基纤维素，羧甲基淀粉，交聚维酮，平均粒径为30〜70μm，90％累积粒径为100〜200μm的低取代羟丙基纤维素中的至少1种 。

公开(公告)号：US20100233265A1

公开(公告)日：2010-09-16

申请号：US12738543

申请日：2008-09-26

申请人： Kai Suzuki

发明人： Kai Suzuki

IPC分类号： A61K31/70 ,  A61K9/10

CPC分类号： A61K9/1635 ,  A61K9/1623 ,  A61K9/20 ,  A61K9/2072 ,  A61K9/2095 ,  A61K31/55

摘要： The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; and (b) a sugar and/or a sugar alcohol, wherein 1 g of the sugar and/or the sugar alcohol can be dissolved in not more than 4 g of water at a water temperature of 20 to 25° C.

摘要翻译： 本发明旨在提供一种具有高水平的释放可控性的基质型固体制剂，其用于抑制上胃肠道中的药物释放并促进下胃肠道中的药物释放，并且解决了由以下组合引起的所有上述缺点： 增塑剂 本发明提供一种基质型药物固体制剂，其包含：（a）甲基丙烯酸类肠溶性聚合物; 和（b）糖和/或糖醇，其中1g和/或糖醇可以在20至25℃的水温下溶解在不超过4g的水中。

公开(公告)号：US10905694B2

公开(公告)日：2021-02-02

申请号：US12665642

申请日：2008-06-20

申请人： Shinsuke Nakagawa ,  Kai Suzuki ,  Tadashi Mukai

发明人： Shinsuke Nakagawa ,  Kai Suzuki ,  Tadashi Mukai

IPC分类号： A61K31/55 ,  A61K9/20 ,  A61K9/16

摘要： The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 μm, and a 90% cumulative particle diameter of 100 to 200 μm.

公开(公告)号：US09072670B2

公开(公告)日：2015-07-07

申请号：US12738543

申请日：2008-09-26

申请人： Kai Suzuki

发明人： Kai Suzuki

IPC分类号： A61K9/14 ,  A01N43/04 ,  A61K31/70 ,  A61K9/16

CPC分类号： A61K9/1635 ,  A61K9/1623 ,  A61K9/20 ,  A61K9/2072 ,  A61K9/2095 ,  A61K31/55

摘要： The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; and (b) a sugar and/or a sugar alcohol, wherein 1 g of the sugar and/or the sugar alcohol can be dissolved in not more than 4 g of water at a water temperature of 20 to 25° C.

摘要翻译： 本发明旨在提供一种具有高水平的释放可控性的基质型固体制剂，其用于抑制上胃肠道中的药物释放并促进下胃肠道中的药物释放，并且解决了由以下组合引起的所有上述缺点： 增塑剂 本发明提供一种基质型药物固体制剂，其包含：（a）甲基丙烯酸类肠溶性聚合物; 和（b）糖和/或糖醇，其中1g和/或糖醇可以在20至25℃的水温下溶解在不超过4g的水中。